Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

InSilico Medicine Debuts on HKEX in $2.3B IPO, Valuing AI Drug Platform at $1.5B

Fineline Cube Dec 18, 2025
Company Deals

Sirnaomics Partners on $42M Small Nucleic Acid Fund in Hangzhou

Fineline Cube Dec 18, 2025
Company Deals

HBM BMS Multi-Specific Antibody Deal Targets $1 Billion Milestones

Fineline Cube Dec 18, 2025
Company Deals

Sanofi Adel Alzheimer’s Deal Targets Phase 1 ADEL-Y01 Antibody

Fineline Cube Dec 18, 2025
Company Deals

Byterna Therapeutics Raises Angel Plus Round for cmRNA CAR‑T Pipeline

Fineline Cube Dec 17, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Fineline Cube Dec 18, 2025
Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Fineline Cube Dec 18, 2025
Company Drug

Alpha Biopharma Completes EVEREST Trial for Zorifertinib in EGFR+ NSCLC with CNS Metastases

Fineline Cube Aug 25, 2022

Shanghai-based Alpha Biopharma announced the completion of the last patient visit in the Phase II/III...

Company Deals

eTheRNA Raises EUR 39M in Series B2 to Expand mRNA Services and Leadership

Fineline Cube Aug 25, 2022

Belgium-based biotech firm eTheRNA has completed a Series B2 financing round, raising EUR 39 million...

Company Drug

Sorrento Therapeutics’ Abivertinib Shows Positive Long-Term Data in NSCLC Trial

Fineline Cube Aug 25, 2022

Sorrento Therapeutics Inc. (OTCMKTS: SRNE) announced positive long-term results for its third-generation EGFR inhibitor abivertinib...

Company Deals

Porton Biologics and Royaltech Med Partner on Bacterial and mRNA Drug Platforms

Fineline Cube Aug 25, 2022

China-based contract development and manufacturing organization (CDMO) Suzhou Porton Biologics Ltd has partnered with Suzhou...

Company Policy / Regulatory

NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall

Fineline Cube Aug 25, 2022

The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...

Company Deals

Biocytogen and Merck KGaA Ink Global Deal for RenMice Platform Licensing

Fineline Cube Aug 25, 2022

Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has entered into a global...

Company

3SBio Inc. Reports H1 2020 Revenue of RMB 3.091B, Net Profit Up 6.19%

Fineline Cube Aug 25, 2022

China-based 3SBio Inc. (HKG: 1530) reported its H1 2020 financial results, with revenue of RMB...

Company

Betta Pharmaceuticals’ H1 2022 Revenues Rise 8.5% on Drug Sales Growth

Fineline Cube Aug 25, 2022

China’s Betta Pharmaceuticals (SHE: 300558) reported RMB 1.25 billion (USD 182.5 million) in revenue for...

Company Drug

Ranok Therapeutics Doses First Patient in RNK05047 Study for BRD4-Targeted Cancers

Fineline Cube Aug 25, 2022

Ranok Therapeutics Co., Ltd, a Hangzhou-based biotech firm, announced that the first patient has been...

Company Drug

CSPC Pharmaceutical’s SYS6006 mRNA Vaccine Shows Strong Safety and Efficacy in Trials

Fineline Cube Aug 24, 2022

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has provided updates on its in-house COVID-19 mRNA...

Policy / Regulatory

China’s Health Commission Promotes Medical-Elderly Care Integration

Fineline Cube Aug 24, 2022

China’s National Health Commission (NHC), National Development and Reform Commission (NDRC), and National Healthcare Security...

Policy / Regulatory

China Passes WHO NRA Evaluation for Vaccine Regulatory System

Fineline Cube Aug 24, 2022

The World Health Organization (WHO) announced that China has successfully passed the evaluation of its...

Company Drug

SinoMab Bioscience’s SN1011 Gets NMPA Nod for NMOSD Trial

Fineline Cube Aug 24, 2022

Hong Kong-based SinoMab Bioscience Ltd (HKG: 3681) has received approval from the National Medical Products...

Company Drug

Mabwell Bioscience Receives NMPA Approval for 6MW3511 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that the National Medical Products Administration...

Company Drug

Bio-Thera Solutions Receives NMPA Approval for BAT8008 Clinical Trial in Solid Tumors

Fineline Cube Aug 24, 2022

Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biotech firm, has received approval from the National Medical...

Company Drug

BeiGene’s Tislelizumab Receives 11th NMPA Filing for First-Line Esophageal Cancer

Fineline Cube Aug 24, 2022

BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) announced that the National Medical Products Administration (NMPA)...

Company Drug

Innovent Biologics Doses First Patient in Australia Trial for PD-1/IL-2 Bispecific Antibody IBI363

Fineline Cube Aug 24, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced that the first patient has been dosed in...

Company Deals

Lee’s Pharma Expands Global Rights to Windtree’s KL4 Surfactant Products

Fineline Cube Aug 24, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has expanded its licensing agreement with US-based Windtree...

Company Deals

Genetron Holdings Receives Buyout Offer from CEO Wang Sizhen at USD 1.36 per ADS

Fineline Cube Aug 24, 2022

Beijing-based precision oncology firm Genetron Holdings Ltd announced receipt of a buyout and take-private offer...

Drug Legal / IP

Supreme People’s Court Rules Against Chugai in China’s First Patent Linkage Case

Fineline Cube Aug 24, 2022

China’s Supreme People’s Court has delivered its verdict in the nation’s first patent linkage dispute,...

Posts pagination

1 … 566 567 568 … 599

Recent updates

  • Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis
  • DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer
  • Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan
  • Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets
  • Asieris’ APL-2401 FGFR2/3 Inhibitor Wins NMPA Nod for Phase 1 Solid Tumor Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Grand Pharmaceutical RDC GPN01530 Wins FDA Phase I/II Nod for FAP Tumor Diagnosis

Company Drug

DualityBio’s DB-1310 Wins FTD as First HER3‑ADC for HR+/HER2‑ Breast Cancer

Company Drug

Yabao’s GLX002 Wins NMPA Approval for PAH Clinical Trial, First Modified Bosentan

Company Drug

Biostar Technologies Doses First Patient in US Pivotal Trial for Utedelone in Breast Cancer Brain Mets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.